Related Experiment Video
Updated: Jun 28, 2026
09:38
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
Case Report: Osimertinib-induced acute interstitial lung disease
Zhiwu Lin1, Liang Wu1, Yang Yu1
1Department of Thoracic Surgery, Ziyang Central Hospital, Ziyang, China.
Frontiers in Pharmacology
|June 20, 2025
Summary
Osimertinib, an EGFR-TKI, can cause severe interstitial lung disease (ILD) in lung cancer patients. Early recognition and intervention are crucial for managing this potentially fatal adverse event.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
- It targets EGFR-TKI-sensitive mutations in lung adenocarcinoma.
- Osimertinib inhibits tumor cell proliferation, migration, and invasion.
Observation:
- A case of osimertinib-induced interstitial lung disease (ILD) is presented.
- An 80-year-old woman with EGFR-mutated lung adenocarcinoma received osimertinib as first-line therapy.
- The patient developed acute dyspnea, pulmonary consolidation, and hypoxemia on day 45.
Findings:
- The patient's condition rapidly deteriorated despite treatment cessation and supportive care.
- The outcome was fatal, highlighting a severe adverse event associated with osimertinib.
- This case emphasizes the risk of ILD in patients treated with EGFR-TKIs.
Implications:
- Monitoring for respiratory symptoms in patients receiving EGFR-TKIs is critical.
- Prompt diagnosis and early intervention for ILD are essential.
- Managing adverse events associated with targeted cancer therapies is vital for patient outcomes.
Related Concept Videos
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:26Pneumothorax-I
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...